Covered by a cent before losses — not after them. The same shape as AGNC’s warning, with credit rather than rates doing the damage: second-quarter distributable earnings before realized gains and losses of $0.48 a share covered the $0.47 quarterly dividend by a single cent, but after $29 million of realized losses — mostly a foreclosed Dallas multifamily loan — distributable earnings were $0.31, well short of the payout. Book value fell 4% in the quarter to $19.31 a share, driven by an $0.80-a-share increase in CECL reserves to $2.43 a share after three new impairments led by a $345 million Chicago office loan. The $0.47 rate was reaffirmed for the third quarter, payable October 15, 2026, but a $0.01 pre-loss margin on a book that just took a reserve hit is a warning with very little room. For a mortgage REIT the House grades core-earnings coverage, book-value trend, and leverage — and management itself warned third-quarter distributable earnings would feel the new impairments and July repayments.
Key risk: Office credit — about $1 billion of watchlist loans, mostly office, decide whether reserves keep rising; one more Chicago-sized impairment wipes out more than a quarter of distributable earnings.
Changes if: Distributable earnings fall below $0.47 for a second quarter, book value falls again, or CECL reserves rise past $2.43 a share. Any of those turns a thin coverage margin into a cut question.
- !Distributable-earnings coverage check: Distributable earnings before realized losses of $0.48 covered the $0.47 dividend by $0.01, but reported distributable earnings of $0.31 did not — realized credit losses are the gap between covered and uncovered.
- ✗Book-value check: Book value fell 4% in one quarter to $19.31, on an $0.80-a-share CECL reserve increase tied to office impairments; the share price at $10.60 is roughly half of book.
- !Leverage and portfolio check: Debt-to-equity rose to 3.9× from 3.7×, office exposure is down to 21% from a 36% peak, and 97% of the $17 billion loan portfolio was performing — the rotation is real, but the watchlist is still about $1 billion.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.